A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 234
Last updated 2026-05-13
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of Pumitamig alone or in combination with Ipilimumab or Cabozantinib in participants with advanced Renal Cell Carcinoma (RCC)
Conditions
- Advanced Renal Cell Carcinoma (RCC)
Interventions
- DRUG
-
Pumitamig
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
Sponsors & Collaborators
- collaborator INDUSTRY
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-03-26
- Primary Completion
- 2029-11-28
- Completion
- 2031-11-26
- FDA Drug
- Yes
Countries
- United States
- Argentina
- Australia
- Brazil
- Canada
- Chile
- Colombia
- Czechia
- Finland
- France
- Germany
- Ireland
- Italy
- Japan
- Mexico
- Romania
- South Korea
- Spain
- Switzerland
- United Kingdom
Study Locations
More Related Trials
-
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
NCT03873402 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
NCT04513522 ·Status: COMPLETED ·Phase: PHASE4
-
A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
NCT07000149 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03141177 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
NCT03291028 ·Status: ACTIVE_NOT_RECRUITING
-
A Research Study for Patients With Metastatic Renal Cell Carcinoma
NCT00106613 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
NCT02420821 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma
NCT03117309 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
NCT02089334 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
NCT02853331 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
NCT02982954 ·Status: COMPLETED ·Phase: PHASE4
-
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
NCT05928806 ·Status: SUSPENDED ·Phase: PHASE2
-
Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)
NCT03177239 ·Status: UNKNOWN ·Phase: PHASE2
-
Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients
NCT06345183 ·Status: COMPLETED
-
A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma
NCT04088500 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma
NCT05805501 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
NCT05361434 ·Status: ACTIVE_NOT_RECRUITING
-
Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
NCT03013335 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
NCT01472081 ·Status: COMPLETED ·Phase: PHASE1
-
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
NCT01354431 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)
NCT00184015 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer
NCT03455452 ·Status: ACTIVE_NOT_RECRUITING
-
A Phase II Study to Treat Subjects With Advanced Renal Cell Carcinoma
NCT00422019 ·Status: COMPLETED ·Phase: PHASE2
-
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
NCT02903914 ·Status: COMPLETED ·Phase: PHASE1
-
Drug Screening Using Novel IMD in Renal Cell Carcinoma
NCT05700461 ·Status: RECRUITING ·Phase: PHASE1